RIGEL PHARMACEUTICALS, INC. Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2023-11-07: Form 10-Q; Exhibit 10.2; Description Amendment No. 1 to the License and Collaboration Agreement.
- 2023-11-07: Form 10-Q; Exhibit 10.1; Description Executive Severance Plan, as amended..
- 2023-08-01: Form 10-Q; Exhibit 10.3; Description Amendments 1, 2 and 3 to License and Transition Services Agreement with Forma Therapeutics, Inc..
- 2023-08-01: Form 10-Q; Exhibit 10.2; Description Rigel Pharmaceuticals, Inc. Inducement Plan, as amended..
| Filed | Form | Exhibit | Description |
|---|
| 2023-11-07 | 10-Q | 10.2 | Amendment No. 1 to the License and Collaboration Agreement |
|---|
| 2023-11-07 | 10-Q | 10.1 | Executive Severance Plan, as amended. |
|---|
| 2023-08-01 | 10-Q | 10.3 | Amendments 1, 2 and 3 to License and Transition Services Agreement with Forma Therapeutics, Inc. |
|---|
| 2023-08-01 | 10-Q | 10.2 | Rigel Pharmaceuticals, Inc. Inducement Plan, as amended. |
|---|
| 2023-08-01 | 10-Q | 10.1 | Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as amended. |
|---|
| 2023-03-07 | 10-K | 10.40 | Offer Letter from Rigel Pharmaceuticals, Inc. to Raymond Furey, dated November 17, 2022. |
|---|
| 2023-03-07 | 10-K | 10.39 | Sublease Agreement with Atara Biotherapheutics, Inc., dated October 28, 2022. |
|---|
| 2023-03-07 | 10-K | 10.38 | Rigel Pharmaceuticals, Inc. Inducement Plan, as amended. |
|---|